Register as a Team to Save 20% On top of Early Bird Rates

AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Targeting the Root Cause of Disease: Applying Precision Biology to Transform Rare & High-Unmet-Need Dermatology Indications

Targeting the Root Cause of Disease: Applying Precision Biology to Transform Rare & High-Unmet-Need Dermatology Indications

11:29 am - Thursday 5th November 2026